Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:38:27.141Z.
Consensus retrieved: 2026-10-06T17:18:15.406Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:38:27.141Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b7fd3b5d8e417d78924f6cd313032c2aac5600bd184120b35a4860f29c1b1599
FORWARD PE RATIO
N/A
Tiziana Life Sciences Ltd
Market Cap
$70.63M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Tiziana Life Sciences Ltd (TLSA) | $70.63M | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $71.23M | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $69.61M | 50.10 |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | N/A |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | N/A |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | N/A |
| iBio, Inc. (IBIO)vs › | $67.52M | N/A |
| Pulmonx Corporation (LUNG)vs › | $75.18M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
Consensus estimates for this stock are reported in USD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
